The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines

Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer

“…PXL, one of the broad spectrum anticancer agents, was selected as a model anticancer drug, due to its efficacy often hampered by acquiring drug resistance by cancer cells [30]. On the other hand, there are different lines of evidence indicating that survivin inhibition enhances the antitumor activity of PXL [20,21].…”

Establishment of Paclitaxel-resistant Breast Cancer Cell Line and Nude Mice Models, and Underlying Multidrug Resistance Mechanisms in Vitro and in Vivo

“…However, paclitaxel is one of first-line chemotherapy drugs for breast cancer treatment-constituting a part of many regular regimens, such as TAC (paclitaxel/adriamycin/ cyclophosphamide), it has a mechanism of action with promoting tubulin polymerization and maintaining it stabilization by inhibiting depolymerization of tubulin and cell mitosis (Saloustros et al, 2008). Furthermore, its efficacy is usually limited by emergence of MDR with continuous application of paclitaxel for treatment of wide range of solid tumors (Podolski-Renić et al, 2011).…”

Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivatives

“…NCI-H460/R cells were selected originally from NCI-H460 cells after 3 months of doxorubicin selective pressure [12]. DLD1-TxR and U87-TxR cells were selected by continuous exposure to stepwise increasing concentrations of paclitaxel (PTX) for a period of 10 and 9 months from DLD1 and U87 cells, respectively [13]. RC6 cells were selected from C6 cells after continuous exposure to stepwise increasing concentrations of carmustine (10-300 µM) for a period of 9 months [14].…”

“…1) on four MDR/non-MDR cancer cell line pairs: three pairs of human cancer [12,13] and a pair of rat glioma cell lines [14], each developed by adaptation to various chemotherapeutics. Besides their cytotoxic activity, pro-oxidative effects of protoflavones as well as their impact on the antioxidative defense system of cancer cells were assessed.…”